1. Home
  2. ORGN vs GLSI Comparison

ORGN vs GLSI Comparison

Compare ORGN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$0.25

Market Cap

109.4M

Sector

Industrials

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$13.40

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGN
GLSI
Founded
2008
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.4M
123.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ORGN
GLSI
Price
$0.25
$13.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$39.00
AVG Volume (30 Days)
1.6M
334.1K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,122,000.00
N/A
Revenue This Year
$49.18
N/A
Revenue Next Year
$144.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$7.78
52 Week High
$1.36
$14.47

Technical Indicators

Market Signals
Indicator
ORGN
GLSI
Relative Strength Index (RSI) 18.76 78.39
Support Level $0.43 $10.00
Resistance Level $0.46 $13.76
Average True Range (ATR) 0.04 1.17
MACD -0.02 0.43
Stochastic Oscillator 0.00 86.56

Price Performance

Historical Comparison
ORGN
GLSI

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: